Boosting Functional Avidity of CD8+ T Cells by Vaccinia Virus Vaccination Depends on Intrinsic T-cell MyD88 Expression but Not the Inflammatory Milieu
Overview
Authors
Affiliations
Unlabelled: T-cell functional avidity is a crucial determinant for efficient pathogen clearance. Although recombinant DNA priming coupled with a vaccinia-vectored vaccine (VACV) boost has been widely used to mount robust CD8+ T-cell responses, how VACV boost shapes the properties of memory CD8+ T cells remains poorly defined. Here, we characterize the memory CD8+ T cells boosted by VACV and demonstrate that the intrinsic expression of MyD88 is critical for their high functional avidity. Independent of selection of clones with high-affinity T-cell receptor (TCR) or of enhanced proximal TCR signaling, the VACV boost significantly increased T-cell functional avidity through a decrease in the activation threshold. VACV-induced inflammatory milieu is not sufficient for this improvement, as simultaneous administration of the DNA vaccine and mock VACV had no effects on the functional avidity of memory CD8+ T cells. Furthermore, reciprocal adoptive transfer models revealed that the intrinsic MyD88 pathway is required for instructing the functional avidity of CD8+ T cells boosted by VACV. Taking these results together, the intrinsic MyD88 pathway is required for the high functional avidity of VACV-boosted CD8+ T cells independent of TCR selection or the VACV infection-induced MyD88-mediated inflammatory milieu.
Importance: Functional avidity is one of the crucial determinants of T-cell functionality. Interestingly, although it has been demonstrated that a DNA prime-VACV boost regimen elicits high levels of T-cell functional avidity, how VACV changes the low avidity of CD8+ T cells primed by DNA into higher ones in vivo is less defined. Here, we proved that the enhancement of CD8+ T cell avidity induced by VACV boost is mediated by the intrinsic MyD88 pathway but not the MyD88-mediated inflammatory milieu, which might provide prompts in vaccine design.
Myeloid MyD88 restricts CD8 T cell response to radiation therapy in pancreatic cancer.
Medler T, Blair T, Alice A, Dowdell A, Piening B, Crittenden M Sci Rep. 2023; 13(1):8634.
PMID: 37244938 PMC: 10224952. DOI: 10.1038/s41598-023-35834-w.
Improving the expansion of human tumor-reactive CD8 + T cells by targeting toll-like receptors.
Chenli Qiu , Wang J, Zhu L, Cheng X, Xia B, Jin Y Front Bioeng Biotechnol. 2022; 10:1027619.
PMID: 36394017 PMC: 9659750. DOI: 10.3389/fbioe.2022.1027619.
Hu Z, Lu S, Lowrie D, Fan X Front Immunol. 2022; 13:895020.
PMID: 35812383 PMC: 9259874. DOI: 10.3389/fimmu.2022.895020.
Therapeutic Vaccines for the Treatment of HIV.
Chen Z, Julg B Transl Res. 2020; 223:61-75.
PMID: 32438074 PMC: 8188575. DOI: 10.1016/j.trsl.2020.04.008.
Teck A, Urban S, Quass P, Nelde A, Schuster H, Letsch A Cancer Immunol Immunother. 2020; 69(7):1217-1227.
PMID: 32157447 PMC: 8222032. DOI: 10.1007/s00262-020-02519-6.